Literature DB >> 19061838

Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer.

Stefano Cairo1, Carolina Armengol, Aurélien De Reyniès, Yu Wei, Emilie Thomas, Claire-Angélique Renard, Andrei Goga, Asha Balakrishnan, Michaela Semeraro, Lionel Gresh, Marco Pontoglio, Hélène Strick-Marchand, Florence Levillayer, Yann Nouet, David Rickman, Frédéric Gauthier, Sophie Branchereau, Laurence Brugières, Véronique Laithier, Raymonde Bouvier, Françoise Boman, Giuseppe Basso, Jean-François Michiels, Paul Hofman, Francine Arbez-Gindre, Hélène Jouan, Marie-Christine Rousselet-Chapeau, Dominique Berrebi, Luc Marcellin, François Plenat, Dominique Zachar, Madeleine Joubert, Janick Selves, Dominique Pasquier, Paulette Bioulac-Sage, Michael Grotzer, Margaret Childs, Monique Fabre, Marie-Annick Buendia.   

Abstract

Hepatoblastoma, the most common pediatric liver cancer, is tightly linked to excessive Wnt/beta-catenin signaling. Here, we used microarray analysis to identify two tumor subclasses resembling distinct phases of liver development and a discriminating 16-gene signature. beta-catenin activated different transcriptional programs in the two tumor types, with distinctive expression of hepatic stem/progenitor markers in immature tumors. This highly proliferating subclass was typified by gains of chromosomes 8q and 2p and upregulated Myc signaling. Myc-induced hepatoblastoma-like tumors in mice strikingly resembled the human immature subtype, and Myc downregulation in hepatoblastoma cells impaired tumorigenesis in vivo. Remarkably, the 16-gene signature discriminated invasive and metastatic hepatoblastomas and predicted prognosis with high accuracy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19061838     DOI: 10.1016/j.ccr.2008.11.002

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  163 in total

Review 1.  Facilitating replication under stress: an oncogenic function of MYC?

Authors:  Steffi Herold; Barbara Herkert; Martin Eilers
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

2.  Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma.

Authors:  Alexander Beck; Corinna Eberherr; Michaela Hagemann; Stefano Cairo; Beate Häberle; Christian Vokuhl; Dietrich von Schweinitz; Roland Kappler
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

Review 3.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.

Authors:  Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Augusto Villanueva; Beatriz Minguez; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

4.  Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets.

Authors:  Masahiro Sekiguchi; Masafumi Seki; Tomoko Kawai; Kenichi Yoshida; Misa Yoshida; Tomoya Isobe; Noriko Hoshino; Ryota Shirai; Mio Tanaka; Ryota Souzaki; Kentaro Watanabe; Yuki Arakawa; Yasuhito Nannya; Hiromichi Suzuki; Yoichi Fujii; Keisuke Kataoka; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Teppei Shimamura; Yusuke Sato; Aiko Sato-Otsubo; Shunsuke Kimura; Yasuo Kubota; Mitsuteru Hiwatari; Katsuyoshi Koh; Yasuhide Hayashi; Yutaka Kanamori; Mureo Kasahara; Kenichi Kohashi; Motohiro Kato; Takako Yoshioka; Kimikazu Matsumoto; Akira Oka; Tomoaki Taguchi; Masashi Sanada; Yukichi Tanaka; Satoru Miyano; Kenichiro Hata; Seishi Ogawa; Junko Takita
Journal:  NPJ Precis Oncol       Date:  2020-07-07

5.  Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription.

Authors:  Shirine Benhenda; Aurélie Ducroux; Lise Rivière; Bijan Sobhian; Michael D Ward; Sarah Dion; Olivier Hantz; Ulrike Protzer; Marie-Louise Michel; Monsef Benkirane; Oliver J Semmes; Marie-Annick Buendia; Christine Neuveut
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

6.  Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes.

Authors:  Gholamreza Bidkhori; Rui Benfeitas; Martina Klevstig; Cheng Zhang; Jens Nielsen; Mathias Uhlen; Jan Boren; Adil Mardinoglu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-27       Impact factor: 11.205

7.  Genomic Profiling Reveals Unique Molecular Alterations in Hepatoblastomas and Adjacent Hepatocellular Carcinomas in B6C3F1 Mice.

Authors:  Sachin Bhusari; Arun R Pandiri; Hiroaki Nagai; Yu Wang; Julie Foley; Hue-Hua L Hong; Thai-Vu Ton; Michael DeVito; Keith R Shockley; Shyamal D Peddada; Kevin E Gerrish; David E Malarkey; Michelle J Hooth; Robert C Sills; Mark J Hoenerhoff
Journal:  Toxicol Pathol       Date:  2015-08-18       Impact factor: 1.902

8.  Molecular classification of hepatocellular carcinoma: potential therapeutic implications.

Authors:  Nicolas Goossens; Xiaochen Sun; Yujin Hoshida
Journal:  Hepat Oncol       Date:  2015

9.  Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.

Authors:  Victoria Tovar; Helena Cornella; Agrin Moeini; Samuel Vidal; Yujin Hoshida; Daniela Sia; Judit Peix; Laia Cabellos; Clara Alsinet; Sara Torrecilla; Iris Martinez-Quetglas; Juan José Lozano; Christèle Desbois-Mouthon; Manel Solé; Josep Domingo-Domenech; Augusto Villanueva; Josep M Llovet
Journal:  Gut       Date:  2015-12-11       Impact factor: 23.059

10.  JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma.

Authors:  Qingshan Chang; Jianguo Chen; Kevin J Beezhold; Vince Castranova; Xianglin Shi; Fei Chen
Journal:  Mol Cancer       Date:  2009-08-17       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.